Hongwei Zhao1,2,3, Romani Richardson1,4, Nazanin Talebloo1,5, Pinku Mukherjee6,7, Ping Wang1, Anna Moore8. 1. Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University, 775 Woodlot Dr., Rm. 3.111, East Lansing, MI, 48823, USA. 2. Shanxi Medical University, Taiyuan, 030001, Shanxi, China. 3. Department of Gynecologic Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, 030013, Shanxi, China. 4. Hofstra University, Hempstead, NY, 11549, USA. 5. Department of Chemistry, College of Natural Science, Michigan State University, East Lansing, MI, 48824, USA. 6. Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA. 7. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA. 8. Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University, 775 Woodlot Dr., Rm. 3.111, East Lansing, MI, 48823, USA. moorea57@msu.edu.
Abstract
PURPOSE: Noninvasive assessment of chemotherapeutic response in colon cancer would tremendously aid in therapeutic intervention of cancer patients and improve outcomes. The aim of the study was to evaluate the feasibility of a noninvasive assessment of chemotherapeutic response by magnetic resonance imaging utilizing underglycosylated mucin 1 (uMUC1) tumor antigen as a biomarker of therapeutic response in a colon cancer mouse model. PROCEDURES: The study was performed by applying molecular imaging approach based on targeting uMUC1 with specific dual-modality imaging probe (MN-EPPT). The probe consisted of dextran-coated iron oxide nanoparticles conjugated to the near infrared fluorescent dye Cy5.5 and to a uMUC1-specific peptide (EPPT) and was used for magnetic resonance imaging (MRI) and fluorescence optical imaging. An orthotopic murine model of colon cancer expressing human uMUC1 peptide (MC38 MUC1) was created along with the control model devoid of the antigen (MC38 neo). Animals received chemotherapy with 5-fluorouracil (5-FU) followed by MN-EPPT-enhanced MR and optical imaging. RESULTS: In vivo imaging of animals with uMUC1 expressing tumors after 5-FU therapy showed that the average deltaT2 was reduced by 7.27 ms (p = 0.045) compared with animals in control groups indicating lower accumulation of MN-EPPT caused by uMUC1 downregulation. In vivo optical imaging, biodistribution, and fluorescence microscopy confirmed the MRI findings. Interestingly, we found that the group of animals that did not respond to chemotherapy ("progressive disease" per RECIST) showed higher accumulation of MN-EPPT compared to the group of responders ("stable disease") consistent with proliferating tumor cells and increased antigen availability. CONCLUSIONS: We believe that in application to over 50 % of human cancers expressing uMUC1, our results could provide insight into overall assessment of therapeutic response based on its expression as defined by non-invasive MN-EPPT-enhanced MRI.
PURPOSE: Noninvasive assessment of chemotherapeutic response in colon cancer would tremendously aid in therapeutic intervention of cancer patients and improve outcomes. The aim of the study was to evaluate the feasibility of a noninvasive assessment of chemotherapeutic response by magnetic resonance imaging utilizing underglycosylated mucin 1 (uMUC1) tumor antigen as a biomarker of therapeutic response in a colon cancer mouse model. PROCEDURES: The study was performed by applying molecular imaging approach based on targeting uMUC1 with specific dual-modality imaging probe (MN-EPPT). The probe consisted of dextran-coated iron oxide nanoparticles conjugated to the near infrared fluorescent dye Cy5.5 and to a uMUC1-specific peptide (EPPT) and was used for magnetic resonance imaging (MRI) and fluorescence optical imaging. An orthotopic murine model of colon cancer expressing human uMUC1 peptide (MC38 MUC1) was created along with the control model devoid of the antigen (MC38 neo). Animals received chemotherapy with 5-fluorouracil (5-FU) followed by MN-EPPT-enhanced MR and optical imaging. RESULTS: In vivo imaging of animals with uMUC1 expressing tumors after 5-FU therapy showed that the average deltaT2 was reduced by 7.27 ms (p = 0.045) compared with animals in control groups indicating lower accumulation of MN-EPPT caused by uMUC1 downregulation. In vivo optical imaging, biodistribution, and fluorescence microscopy confirmed the MRI findings. Interestingly, we found that the group of animals that did not respond to chemotherapy ("progressive disease" per RECIST) showed higher accumulation of MN-EPPT compared to the group of responders ("stable disease") consistent with proliferating tumor cells and increased antigen availability. CONCLUSIONS: We believe that in application to over 50 % of human cancers expressing uMUC1, our results could provide insight into overall assessment of therapeutic response based on its expression as defined by non-invasive MN-EPPT-enhanced MRI.
Entities:
Keywords:
Colon cancer; In vivo molecular imaging; Targeted nanoparticles; Underglycosylated mucin 1 tumor antigen (uMUC1)
Authors: P Mukherjee; L B Pathangey; J B Bradley; T L Tinder; G D Basu; E T Akporiaye; S J Gendler Journal: Vaccine Date: 2006-11-16 Impact factor: 3.641
Authors: Ping Wang; Byunghee Yoo; Sarah Sherman; Pinku Mukherjee; Alana Ross; Pamela Pantazopoulos; Victoria Petkova; Christian Farrar; Zdravka Medarova; Anna Moore Journal: Int J Cancer Date: 2016-04-15 Impact factor: 7.396
Authors: Ruben D Houvast; Mireille Vankemmelbeke; Lindy G Durrant; Manfred Wuhrer; Victor M Baart; Peter J K Kuppen; Lioe-Fee de Geus-Oei; Alexander L Vahrmeijer; Cornelis F M Sier Journal: Cancers (Basel) Date: 2020-12-21 Impact factor: 6.639